Т. С. Константинова
A5103118399- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Iron Metabolism and Disorders
- Multiple Myeloma Research and Treatments
- Hemoglobinopathies and Related Disorders
- Childhood Cancer Survivors' Quality of Life
- Acute Myeloid Leukemia Research
- Peptidase Inhibition and Analysis
- Lung Cancer Research Studies
- Erythrocyte Function and Pathophysiology
- Cancer Treatment and Pharmacology
- Trace Elements in Health
- Neutropenia and Cancer Infections
- Eosinophilic Disorders and Syndromes
- Complement system in diseases
- Hemoglobin structure and function
- Renal Diseases and Glomerulopathies
- Hematopoietic Stem Cell Transplantation
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Mechanisms and Therapy
- Neonatal Health and Biochemistry
- Protein Degradation and Inhibitors
- Retinoids in leukemia and cellular processes
- Lung Cancer Treatments and Mutations
Regional Children's Clinical Hospital No. 1
2015-2024
Institute of Biochemical Physics NM Emanuel
2024
Regional Children's Hospital No1
2020-2023
Clinical Hospital No. 8
2022
Ural State Medical University
2010-2020
Ministry of Health of the Russian Federation
2016
Voronezh State University
2005
National Medical Research Center for Hematology
2003
Currently, the main pathogenetic method for treatment of paroxysmal nocturnal hemoglobinuria (PNH) is with recombinant monoclonal antibodies that block C5 component complement system. Eculizumab first biotechnological drug, which a antibody, proven clinical efficacy and safety patients PNH, used in world practice. In Russia, framework state program Development pharmaceutical medical industry 20132020 was developed Elizaria (JSC GENERIUM) biosimilar original drug eculizumab. Aim.To evaluate...
Abstract The IKEMA study (Randomized, Open Label, Multicenter Study Assessing the Clinical Benefit of Isatuximab Combined With Carfilzomib [Kyprolis®] and Dexamethasone Versus in Patients Relapse and/or Refractory Multiple Myeloma Previously Treated 1 to 3 Prior Lines; #NCT03275285) was a randomized, open-label, multicenter phase investigating isatuximab plus carfilzomib dexamethasone (Isa-Kd) vs Kd patients with relapsed multiple myeloma. This subanalysis analyzed depth response Isa-Kd Kd....
The study aimed to assess the safety, immunogenicity, and efficacy of long-term therapy with biosimilar eculizumab (Elizaria®) in PNH patients.
Background . The effectiveness of therapy for acute T-lymphoblastic leukemia (T-ALL) and lymphoma (T-LBL) has significantly improved over the past decades, including through implementation hematopoietic stem cell transplantation (HSCT). Russian multicenter ALL-2009 study (ClinicalTrials.gov NCT01193933) showed that performing autologous HSCT (auto-HSCT) in patients with T-ALL/LBL improves long-term results. However, was non-randomized need auto-HSCT clinical practice requires careful study....
to analyze well-known risk factors (RFs), such as age, immunophenotype, baseline leukocytosis, enhanced lactate dehydrogenase (LDH) activity, time achieve complete remission, a group, and cytogenetic abnormalities) in patients with acute lymphoblastic leukemia (ALL) the use of ALL-2009 protocol.The protocol covered 298 (137 women (including 13 pregnant women) 161 men) aged 15 55 years (median age 28 years) Ph-negative ALL. The phenotype was unknown 6 patients. Three (1%) were ascertained...
An interim analysis of long-term treatment results for 202 patients with acute lymphoblastic leukemia (ALL), aged 15–60 years, received therapy according protocol ALL-2009 was shown. The basic principle non-aggressive, but continued cytostatic exposure, as well as the reproducibility in a regional hematology centers. Long-term are 2 times higher than previously obtained adult ALL within Russian clinical multicenter studies ALL. 5‑year overall survival patients younger 30 years 73.6 %,...
Introduction. Over the past 5 years, signifi cant progress has been achieved in treatment of patients with Ph-negative acute lymphoblastic leukemia (ALL). Treatment results were compared between two protocols Russian multicenter studies «ALL-2009» and «ALL-2016», which multicomponent high-dose consolidation was not used. The principle continuity observed modifi cation doses cytostatic drugs depending on depth cytopenia. Aim – to compare 5-year determine factors unfavorable prognosis ALL....
To analyze the efficiency of ALL-2009 protocol (ClinicalTrials.gov NCT01 193933) in patients with T-cell leukemias, particularly role autologous hematopoietic stem cell transplantation (auto-HSCT) after non-myeloablative BEAM conditioning, followed by maintenance therapy.Since 2009, study has enrolled 90 acute lymphoblastic leukemia (T-ALL), treatment results were assessed 86 patients: 6 and 28 underwent allogeneic HSCT auto-HSCT, respectively. A landmark analysis was used to compare...